The Technical Analyst
Celldex Therapeutics Inc [CLDX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Celldex Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.36% $36.13
America/New_York / 26 apr 2024 @ 10:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 327.39 mill |
| EPS: | -2.86 |
| P/E: | -12.63 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 64.42 mill |
| Avg Daily Volume: | 0.947 mill |
| RATING 2024-04-25 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.63 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.15x |
| Company: PE -12.63 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-4.62 (-112.78%) $-40.75 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 34.11 - 37.99 ( +/- 5.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-13 | Jimenez Freddy A. | Buy | 20 000 | Common Stock |
| 2024-02-13 | Jimenez Freddy A. | Buy | 4 166 | Common Stock |
| 2024-02-13 | Jimenez Freddy A. | Sell | 4 166 | Incentive Stock Option (Right to Buy) |
| 2024-02-13 | Jimenez Freddy A. | Sell | 20 000 | Incentive Stock Option (Right to Buy) |
| 2024-01-02 | Martin Samuel Bates | Buy | 10 750 | Common Stock |
| INSIDER POWER |
|---|
| 75.17 |
| Last 97 transactions |
| Buy: 2 900 849 | Sell: 507 801 |
Forecast:
11:59 - $36.00
Live Trading Signals (every 1 min)
Forecast
1: 10:29 - $36.15
Forecast 2: 11:19 - $36.13
Forecast 3: 11:59 - $36.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $36.13 (-0.36% ) |
| Volume | 0.0188 mill |
| Avg. Vol. | 0.947 mill |
| % of Avg. Vol | 1.981 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $37.40 | N/A | Active |
|---|
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest Press Releases
2024-04-17 08:01:00 - Press Release
Celldex Announces Completion Of Enrollment In Phase 2 Study Of Barzolvolimab In Patients With Chronic Inducible Urticaria
Hampton, n.j., april 17, 2024 (globe newswire) -- celldex therapeutics, inc. (nasdaq:cldx) today announced that patient enrollment has been completed in the company's phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (cindu)—cold urticaria (coldu) and symptomatic dermographism (sd). cindu is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—temperatures below skin temperature in coldu and scratching/rubbing of the skin in sd. mast cell activation is known to be a critical driver in coldu and sd. barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase kit with high specificity and potently inhibits its activity, which is required for mast cell function and survival...
2024-03-08 07:00:00 - Press Release
Celldex Therapeutics To Participate In The Leerink Partners Global Biopharma Conference
Hampton, n.j., march 08, 2024 (globe newswire) -- celldex therapeutics, inc. (nasdaq:cldx) announced today that management will participate in a fireside chat at the leerink partners global biopharma conference on monday, march 11, 2024 at 10:00 a.m. et.
2024-03-05 10:30:00 - Press Release
Celldex Therapeutics To Present At Td Cowen's 44th Annual Health Care Conference
Hampton, n.j., march 05, 2024 (globe newswire) -- celldex therapeutics, inc. (nasdaq:cldx) announced today that anthony s. marucci, president and chief executive officer will participate in an “inflammation & immunology corporate panel discussion” at td cowen's 44th annual health care conference. the panel will be held on tuesday, march 5, 2024 from 2:10 to 3:10 pm et.
2024-03-05 10:10:00 - Press Release
Celldex Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Hampton, n.j., march 05, 2024 (globe newswire) -- celldex therapeutics, inc. (“celldex” or the “company”) (nasdaq: cldx) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share. all of the shares sold in the offering were sold by celldex. the gross proceeds to celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.
2024-02-29 21:14:00 - Press Release
Celldex Therapeutics Announces Pricing Of Upsized $400 Million Public Offering Of Common Stock
Hampton, n.j., feb. 29, 2024 (globe newswire) -- celldex therapeutics, inc. (“celldex” or the “company”) (nasdaq: cldx) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share. all of the shares to be sold in the offering are to be sold by celldex. in connection with the offering, celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions. the company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters' option, if any, of approximately $400...
Latest News
2024-04-09 10:36:08 - Zacks Investment Research
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2024-04-08 13:01:10 - Zacks Investment Research
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-04-08 10:35:20 - Zacks Investment Research
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-03-20 10:56:04 - Zacks Investment Research
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-05 10:30:00 - GlobeNewsWire
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Inflammation & Immunology Corporate Panel Discussion” at TD Cowen's 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024 from 2:10 to 3:10 PM ET.
2024-02-29 13:01:25 - Zacks Investment Research
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-02-29 10:56:07 - Zacks Investment Research
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-02-26 09:11:04 - Zacks Investment Research
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.
2024-01-29 10:45:00 - Seeking Alpha
MoneyShow's Best Investment Ideas For 2024: Part 3
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.
2024-01-26 17:30:00 - Seeking Alpha
MoneyShow's Best Investment Ideas For 2024: Part 2
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.